中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗丙型肝炎病毒小分子化合物的研究进展

董志霞 谢青

董志霞, 谢青. 抗丙型肝炎病毒小分子化合物的研究进展[J]. 临床肝胆病杂志, 2011, 27(1): 19-22.
引用本文: 董志霞, 谢青. 抗丙型肝炎病毒小分子化合物的研究进展[J]. 临床肝胆病杂志, 2011, 27(1): 19-22.
Dong ZhiXia, Xie Qing. New development of small molecule compounds for hepatitis C therapy[J]. J Clin Hepatol, 2011, 27(1): 19-22.
Citation: Dong ZhiXia, Xie Qing. New development of small molecule compounds for hepatitis C therapy[J]. J Clin Hepatol, 2011, 27(1): 19-22.

抗丙型肝炎病毒小分子化合物的研究进展

详细信息
  • 中图分类号: R512.63

New development of small molecule compounds for hepatitis C therapy

  • 摘要:

    目前慢性丙型肝炎(CHC)的标准疗法为聚乙二醇干扰素-α(PEG-IFN-α)联合利巴韦林,但该疗法存在一定的局限性。近年来针对HCV生活周期的小分子抗病毒药物迅速发展,给将来的治疗带来了新的希望。

     

  • [1]Seeff LB.Natural history of hepatitis C[J].Hepatology,1997,26(3 Suppl 1):S21-28.
    [2]Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567.
    [3]Lauer GM,Walker BD.Hepatitis C virus infection[J].N Engl J Med,2001,345(1):41-52.
    [4]Perz JF,Armstrong GL,Farrington LA,et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol,2006,45(4):529-538.
    [5]Hoofnagle JH,Mullen KD,Jones DB,et al.Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon.A preliminary report[J].N Engl J Med,1986,315(25):1575-1578.
    [6]Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,Antwerp,Belgium[J].JViral Hepat,1999.6(1):35-47.
    [7]Lindenbach BD,Rice CM.Unravelling hepatitis C virus replication from genome to function[J].Nature,2005,436(7053):933-938.
    [8]Kwong AD,McNair L,Jacobson I,et al.Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors[J].Curr Opin Pharmacol,2008,8(5):522-531.
    [9]Reesink HW,Zeuzem S,Weegink CJ,et al.Rapid decline of viral RNA in hepatitis C patients treated with VX-950:a phase Ib,placebo-controlled,randomized study[J].Gastroenterology,2006,131(4):997-1002.
    [10]Zeuzem S.Telaprevir,peginterferon alfa-2a,and ribavirin for 28 days in chronic hepatitis C patients[J].J Hepatol,2008,49(2):157-159.
    [11]de Bruijne J,Weegink CJ,Jansen PL,et al.New developments in the antiviral treatment of hepatitis C[J].Vox Sang,2009,97(1):1-12.
    [12]Kwo P.HCV SPRINT-1:boceprevir plus peginterferon-alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008.
    [13]Schiff E,Poordad F,Jacobson I,et al.Boceprevir(B)combination therapy in null responders(NR):Response dependent on interferon responsiveness[J].J Hepatology,2008,48(2):S46.
    [14]Reddy R.Antiviral activity,pharmacokinetics,safety,and tolerability of R7128,a novel nucleoside HCV RNA polymerase inhibitor,following multiple,ascending oral doses inpatients with HCV genotype 1 infection who have failed prior interferon therapy[R].The 57th Annual Meeting of the American Association for the Study of Liver Diseases,2006.
    [15]Nicolas O.Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759[R].The 41st Annual Meeting of the European Association for the Study of the Liver,2008.
    [16]Nettles R.BMS-790052 is a first-in-class potent hepatitis C virus(HCV)NS5A inhibitor for patients with chronic HCV infection:Results from a proof-of-concept study[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases,2008.
  • 加载中
计量
  • 文章访问数:  4471
  • HTML全文浏览量:  6
  • PDF下载量:  1371
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回